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Aims and Objectives. Metabolic dysregulation has failed to explain clinical variability of patients with diabetic nephropathy
and hence a renewed interest emerged in haemodynamic factors as determinant of progression and development of diabetic
nephropathy. We therefore studied for various factors which can correlate with raised renal vascular resistance in diabetic
nephropathy. Material and Methods. Renal vascular resistance was measured in patients with established and incipient diabetic
nephropathy and compared with controls using noninvasive color Doppler examinations of intrarenal vasculature. Results.R e n a l
vascular resistance correlated with age, duration of disease, GFR, serum creatinine, and stage of retinopathy. Renal vascular
resistance was signiﬁcantly reduced in patients on treatment with RAAS inhibitors and insulin, than those on OHA and
antihypertensives other than RAAS inhibitors. Conclusion. The study implies that renal vascular resistance may help identify
diabetics at high risk of developing nephropathy, and these set of patients could be candidates for RAAS inhibition and early
insulin therapy even in patients without albuminuria.
1.Introduction
Diabetes and its complications pose an immense amount
of social and economic burden on the health infrastructure
and resources throughout the globe. Diabetic nephropathy
is the single most common cause of end-stage renal disease
(ESRD) throughout the globe accounting for a whooping
25–45% of all patients enrolled in ESRD programmes [1].
Diabetic nephropathy is also a leading cause of chronic kid-
ney disease (CKD) in India accounting for about 30% of all
CKD patients [2]. Recent estimates suggest that soon India,
China, and United States are and will remain the countries
with largest number of diabetics [3].
In spite of several decades of research since 1940’s when
several studies linked diabetes to renal disease [4, 5], there
are still large gaps in the knowledge and understanding of
pathophysiology of diabetic nephropathy.
One of the intriguing controversies has been that which
patients of diabetes (type 1/type 2) are predisposed and are
likely to progress to diabetic nephropathy. Several studies
have demonstrated that only about 40% of patients of Type
1 and Type 2 diabetes have renal involvement. These set of
patients that progress to frank diabetic nephropathy have
been labeled as “progressors” and the other set of patients
that in spite of similar control of blood sugar and long-term
poor glycemic control do not progress have been labeled as
“nonprogressors” [6].
There has been a paradigm shift in the understanding of
factors held responsible for this discrepancy in the natural
history of these two sets of patients with the balance tilting
towardshemodynamic factorsratherthantowardsmetabolic
factors [7]. The other, controversy in diabetic nephropathy
surrounds the concept of microalbuminuria. Albuminuria
has been linked to diabetic renal disease as early as 1836 by
Bright [8]. Several studies have established microalbumin-
uria as a hallmark of diabetic nephropathy and microalbu-
minuria has been used as a predictive marker for progressive
decline in renal function [9–11], however few researchers2 International Journal of Vascular Medicine
have challenged its signiﬁcance especially after studies
showed that many patients of diabetic nephropathy with
advanced renal disease never develop albuminuria [12–14]
and also 58–68% patients with microalbuminuria regress
over a period of time to normoalbuminuria [15, 16].
Another area of active research has been ﬁnding suitable
markers for predicting which patients will progress. Many
studies addressed biochemical markers but none is speciﬁc
or sensitive enough for clinical use [17–19].
Of late researchers have tried to answer all these con-
troversiesbyasinglekeyandthatishemodynamicalterations
[20] which include concepts of intraglomerular hyperten-
sion, raised renal vascular resistance and so called ischemic
nephropathy, which have been held responsible for discrep-
ancy in behavior of various groups; recently an article by
Nosadini et al. established renal vascular resistance as a pre-
dictive marker for progressive disease [6].
Prompted with above considerations, we designed our
study to evaluate renal vascular resistance with noninvasive
Doppler in 57 diabetic patients attending a tertiary care
centre in India.
2.MaterialandMethods
This study was carried out in the Department of Medicine
and Radiology, Sir Sunderlal Hospital, Institute of Medical
sciences (IMS), Banaras Hindu University (BHU) from May
2008 to June 2010. The study protocol was approved by the
research and ethical committee of the institute and written
informed consent was taken from all patients.
A total 31 patients of diabetic nephropathy with stable
disease, and three groups of control subjects (19 healthy
subjects, 14 diabetics without microalbuminuria, and 12
diabetics with microalbuminuria) were included in the
study. Diabetes was diagnosed as per WHO guidelines
[21]. All of our patients were of type 2 diabetes. Diabetic
nephropathy was labeled clinically satisfying the following
criteria: (a) evidence of retinopathy on fundus examination,
and (b) persistent albuminuria > 300mg/24hrs or persistent
proteinuria > 500mg/dl on urine analysis on two separate
occasions 3 months apart.
Microalbuminuria deﬁned as 24 hr urinary albumin 30–
300μg/dl. 24hr urinary collection was done from 8AM
to 8AM next day with morning urine of day of start of
collection discarded and morning urine of next morning
collected. Adequacy of collection was conﬁrmed by 24hr
urinary creatinine estimation wherever necessary. Urine
routine microscopy and urine cultures were done before
estimation of 24hr urinary protein to rule out urinary
tract infection. Patients with diabetic foot, valvular heart
disease, ischemic heart disease, glomerulonephritis, lupus
nephritis, renal calculi, hydronephrosis, renal masses, cere-
brovascular, cardiovascular, and peripheral vascular disease
were excluded.
2.1. Doppler Study.
(1) Pulsed Doppler study of interlobar and arcuate
arteries was performed on bilateral kidneys.
Resistive Index (RI). Peak systolic frequency shift—min-
imum diastolic frequency shift/Peak systolic frequency shift
during whole cardiac cycle.
Pulsatility Index (PI). Peak systolic frequency shift—min-
imum diastolic frequency shift/Mean frequency during the
whole cardiac cycle.
We used a Toshiba NEMIO-30 Doppler machine and
recorded ﬁndings with the help of a curvilinear probe of
3.75Mhz. The sonologist was unaware of the group to which
the patient belonged. RI and PI readings 2 each per vessel
(interlobar arteries) for both kidneys were recorded and
average of all 4 readings was taken for study purposes.
B mode ultrasound was also done to look for renal size
length, breath, and thickness. Patients with anatomical renal
artery stenosis of the renal artery (main) were excluded from
the study. Wall ﬁlter was set to a minimum of 50Hz and
with a Doppler sample volume set at 2–4mm, minimum
pulse repetition frequencies that did not produce aliasing
were used with readings noted from existing software in the
machine and all readings done at minimum possible angle
betweenultrasoundbeamandthevessel.Patientswererested
for 5min before taking any Doppler reading and all readings
made while subject was lying in supine position with the
breath held in deep end inspiration. Subjects were required
toholdtheirbreathwhilereadingswerebeingtakentoobtain
adequate spectral waveforms. Readings of RI and PI were
made after a minimum of 4 identical consecutive spectral
waveforms were achieved. Reproducibility of Doppler read-
ings was assessed byintraobserverandinterobservervariance
which was 3.9% and 5.0%, respectively.
Manysubjectscouldnotcooperateinthestudyandcould
not hold breaths adequately and were removed from the
study especially patients with morbid obesity, respiratory
problems, and so forth. This may be the reason for a non-
intentional lower mean BMI values in our study population.
Blood pressure was recorded after a 5min rest just
before theDopplerexamination in right armsupine position
and a second reading was made 5min after the Doppler
examination was completed. Averagevalues of both readings
were recorded. Mean blood pressure was calculated for
comparison purposes. A standard health questionnaire was
completed which included type, duration of diabetes, treat-
ment history, and other signiﬁcant illness like hypertension
and coronary artery disease were also enquired into.
Patients with proteinuria had to have proteinuria on two
occasions three months apart; they were put on adequate
and necessary treatment in the ﬁrst visit and most of them
continued treatment till the next visit, therefore labeling a
patientas“oninsulin”or“onOHA ”or“ onACE/ARB”meant
they were on that treatment for at least 3 months.
Other patient variables like age, 24 hour urinary pro-
tein/albumin, HbA1c% values, fundus examination, lipid
proﬁle, and anthropometric measurements were also re-
corded. Serum glucose level (FBS, PPBS) was estimated
by glucose oxidase/glucose peroxidase method and Serum
lipid parameters (total cholesterol, HDL-C, LDL-C, very
low density lipoprotein, and triglyceride) were quantiﬁed
by commercially available Kits (Span diagnostics, India)International Journal of Vascular Medicine 3
Table 1: Baseline characteristics of diﬀerent groups.
Variable Diabetic nephropathy
(Group A) (n = 31)
Diabetics with
microalbuminuria
(Group B)
(n = 14)
Diabetics without
microalbuminuria
(Group C)
(n = 12)
Nondiabetic
controls
(n = 19)
P-value
Age (yrs)
Median ± IQR 58 ±14.25 60 ±15 58.50 ±15 50.00 ±22.25 .059 (NS)
Sex Ratio (M/F) 20/11 7/7 10/2 13/6 .351 (NS)
Duration of diabetes (yrs)
Median ± IQR 7.00 ±11.25 3.5 ±11.75 2.5 ±19.25 — .179 (NS)
BMI (Kg/m2)
Mean ± SD 22.416 ±4.218 22.451 ±4.007 24.008 ±4.756 21.872± 3.974 .581 (NS)
Treatment diabetes
(OHA/Insulin) 21/10 9/59 /2 — .602 (NS)
Treatment hypertension
(ACE or ARB/others) 9/22 8/6 0/12 1/18 <.001
Serum Creatinine
Median ± IQR 1.9 ±2.11 .2 ±1.21 ± 0.40 .9 ±0.1 <.001
GFR (ml/min)
Mean ± SD 37.134± 23.54 8 .383 ±21.042 71.456 ±32.666 78.455 ±18.96 <.001
FBS (mg/dl)
Median ± IQR 170 ±130.5 180 ±100 157 ± 74.57 8 ±15 <.001∗
Hb1Ac (%)
Median ± IQR 8.5 ±3.15 8.0 ±2.27 .15 ±1.55 4.1 ±0.3 <.001∗
Cholesterol (mg/dl)
Median ± IQR 106 ±28.5 102.5 ±75 73.5 ±44 73 ± 9.75 <.001∗∗
Triglyceride (mg/dl)
Median ± IQR 120 ±126 127 ±153 102 ± 97.58 8 ±20 .144
Mean blood pressure (mmHg)
Mean ± SD 96.75 ±12.19 7 .95 ±10.59 2 .5 ±10.195 97.36 ±16.16 .691 (NS)
Fundus staging (early/late)
Early = stage 1&2
Late = stage 3&4
19/12 8/2∗ 3/0∗ — .256 (NS)
∗There was no signiﬁcant diﬀerence between groups A, B, and C.
∗∗There was no signiﬁcant diﬀerence between A and B, but signiﬁcant diﬀerence between A and C, and between B and C.
usingmanufacturer’s protocolusingAutoanalyzer(FlexorXL
machine, Vitro sciences). HbA1c% was measured in venous
sample after an overnight fast by D10 Bio-rad system auto-
mated machine using HPL-C technique of electrophoresis.
All the biochemical testswere performed inhospital’s central
biochemical laboratory.
Fundus examination was done by an ophthalmologist
who did not know the group under which the patient felt.
Staging of the disease was done according to International
ClinicalDiabeticRetinopathyDiseaseSeverityScale.Weused
the GAULT COCKROFTFORMULA to calculate GFR.
3.StatisticalAnalysis
All the data were reported as mean ± standard deviation
if they were normally distributed and as median ± Inter
Quartile Range (IQR) if they were not normally distributed.
One way ANOVA was applied when comparing parametric
variables (mean) between four groups. Kruskal-wallis one
way Anova was used to compare median values between
groups if data was not normally distributed. Pearson’s
correlation was used to see corelation of RI and PI with
various variables. Multivariate linear and stepwise forward
progression analysis was done using RI and PI as dependent
variables and other variables as independent variables.
Subgroup analysis was done using unpaired student’s “t”-
test between two groups. Chi square test was used for rates
and proportions, however if >20% values were under 5,
Fisher exact test was used. Mann Whitney test was used for
nonparametric variables between two groups. P-value <.05
was ascribed as signiﬁcant diﬀerence between groups. Data
were analyzed by the sigma stat software version 3.5.
4.Results
The baseline characteristics showed that a signiﬁcant dif-
ference between the groups existed in serum cholesterol,
GFR, and treatment of hypertension. Patients with diabetic
nephropathy and diabetics with microalbuminuria had
higher levels of serum cholesterol than patients without
microalbuminuria. GFR showed progressive decline from
diabetes without albuminuria to diabetic nephropathy.4 International Journal of Vascular Medicine
Table 2: Comparison of RI and PI between groups.
Diabetic
nephropathy
Diabetics with
microalbuminuria
Diabetics without
microalbuminuria
Nondiabetic
controls P-value
RI
Median ± IQR 0.825 ±0.178 0.742 ±0.21 0.74 ±0.169 0.64 ±0.097 <.001
PI
Median ± IQR 1.86 ±0.82 1.388 ±0.67 1.263 ±0.35 1.075 ±0.39 <.001
Table 3: Correlation of RI and PI with various variables.
Index Parameter Correlation coeﬃcient P-value
RI Age 0.329 .003
PI Age 0.383 .000
RI BMI −0.0235 .840
PI BMI 0.0221 .849
RI Duration −0.149 .266
PI Duration 0.0005 .997
RI Diastolic blood pressure −0.002 .985
PI Diastolic blood pressure −0.032 .78
RI Systolic blood pressure 0.0265 .820
PI Systolic blood pressure −0.0188 .871
RI Mean blood pressure 0.001 .988
PI Mean blood pressure −0.0385 .740
RI Fasting Blood sugar −0.145 .281
PI Fasting Blood sugar −0.178 .183
RI Cholesterol −0.162 .227
PI Cholesterol −0.0475 .725
RI Triglyceride −0.143 .289
PI Triglyceride −0.129 .339
RI Serum creatinine 0.368 .001
PI Serum creatinine 0.479 .000
RI GFR −0.456 .000
PI GFR −0.534 .000
RI Fundus stage 0.425 .001
PI Fundus stage 0.525 .000
Patients with diabetes without microalbuminuria although
had mean values lower than control population but there
were values above values in normal population signifying
presence of hyperﬁltration early in diabetes. Patients in dia-
betic nephropathy group had 9 patients receiving ACE/ARB,
others were receiving other antihypertensive as either these
patients had contraindications to use of this drug or could
not tolerate the drug. Higher percentages of patients in dia-
betes with microalbuminuria group were on ACE inhibitors.
Patients in this group who were not on ACE inhibitors
were again those in whom it was contraindicated or not
tolerated or patients who did not comply with the advised
treatment. Duration of disease was not signiﬁcantly diﬀerent
in the various groups signifying that in spite of long
duration of diabetes many patients did not develop diabetic
nephropathy and still remained in the group of diabetes
without microalbuminuria, the median duration of disease
in this group was 2.5 ± 19.25yrs, which was nonsigniﬁcantly
lower than other groups (Table 1).
Table 4: Comparison of patients with or without raised vascular
resistance.
Characteristics R.I ≥ 0.8 (n = 30) RI < 0.8
(n = 27) P value
Age
Mean ± SD 59.467 ±10.837 56.11 ± 8.243 .198
Sex ratio (M/F) 19/11 18/9 .988
BMI
Median ± IQR 21.458 ±3.895 22.862 ±6.431 .179
Duration
Median ± IQR 5 ±91 0 ±19 .381
Mean B.P.
(Mean ± SD) 95.289 ±12.508 97.11 ±10.005 .549
FBS
Median ± IQR 160 ±88 170 ±88.5 .406
Fundus staging
(early/late)
Early = stage 0, 1&2
Late = stage 3&4
20/10 22/4 .216
GFR
Mean ± SD 42.741 ±24.043 50.79 ±29.474 .261
Treatment category
(OHA/Insulin) 26/41 4 /13 .010
Treatment
hypertension
(ON ACE or
ARB/others)
8/22 11/16 .399
Themeanresistiveindex(RI)valuesofinterlobararteries
showed a statistically signiﬁcant diﬀerence (P<. 001)
between each group except between group B and group C
that is no signiﬁcant diﬀerence was seen between subjects
with microalbuminuria andsubjectswithoutmicroalbumin-
uria. This would imply that RI values start increasing in dia-
betic subjects even before appearance of microalbuminuria.
The mean values of pulsatility index (PI) of interlobar
arteries werealsostatisticallysigniﬁcantlyraisedascompared
to nondiabetics (P<. 001) but intragroup diﬀerences were
signiﬁcant only between subjects with diabetic nephropathy
and diabetics without microalbuminuria (Table 2).
RI and PI on univariate analysis correlated signiﬁcantly
with age, serum creatinine, GFR, stage of diabetic retinopa-
thy, and treatment group for diabetes; patients on insulin
having lower values of RI and PI, on multivariate linear
analysis and multivariate stepwise forward progression using
RI and PI as dependent variable RI and PI correlated with
age, serum creatinine, and GFR (Table 3).International Journal of Vascular Medicine 5
Table 5: Comparison of patients between treatment groups.
Characteristics On
insulin∗(n = 17)
On OHA∗
(n = 40) P-value
Age
Mean ± SD 57 ±7.508 58.25 ±10.636 .662
Sex ratio (M/F) 10/72 7 /13 .745
BMI
Mean ± SD 23.652 ±4.014 22.381± 4.35 .307
Duration 10 ±19.188 5 ±11 .88
Mean B.P
Mean ± SD 96.039 ±11.699 96.2 ±11.391 .961
Hb1Ac
Median ± IQR 8.3 ±2.77 .55 ± 2.6 .341
FBS
Median ± IQR 200 ±117 160.5± 76.5 .140
Fundus staging
(early/late)
Early = stage 0,
1&2
Late = stage 3&4
13/43 0 /10 1
GFR
Mean ± SD 51.889 ±32.596 45.725 ±25.164 .443
Treatment
hypertension
(ON ACE or
ARB/others)
8/91 1 /29 .260
RI
Median ± IQR 0.703 ±0.117 0.835 ±0.182 .001
PI
Median ± IQR 1.33 ±0.490 1.742 ±0.974 .094
Proteinuria
(mg/day)
Median ± IQR
600 ±2862 540.5 ±648 .291
There was also signiﬁcant co relation of stage of retinal
disease with RI and PI values (P<. 001) (Spearman co
relation coeﬃcient). On multiple comparison tests there was
signiﬁcant diﬀerence between RI values of stage 4 versus
normal and Stage 2 versus normal; PI also correlated with
stage of fundal disease with higher values in higher retinal
stage (P<. 001). On multiple comparison tests there was
signiﬁcant diﬀerence between PI values of stage 4 versus
normal, Stage 3 versus normal, stage 2 versus normal, and
stage 2 versus stage 1.
Subgroup analysis of diabetic subjects on basis of RI
values showed that the groups diﬀered signiﬁcantly only in
the treatment received for diabetes with patients with sig-
niﬁcant proportion of patients with RI < 0.8 on Insulin
therapy (Table 4).
On classifying diabetic patients according to treatment
received patients on insulin therapy had signiﬁcantly lower
values of RI than patients on OHA’s in spite of having sim-
ilar blood sugar controls in form of almost same HbA1c%
levels. However fasting blood sugar levels were signiﬁcantly
higher in patients on insulin. Therefore in spite of equal or
even poor glycemic control patients on insulin had lower RI
values. PI values were also nonsigniﬁcantly lower in patients
on insulin (1.33 versus 1.74) (Table 5).
5.Discussion
Our study did not show any co relation of RI or PI
values with BMI, Sex, FBS, HbA1c,serum cholesterol, serum
triglyceride, duration of disease, or mean blood pressure.
Barring a few studies our results are in accordance with
many similar studies on this topic. These ﬁndings suggest
thatthereare factorsotherthanthelevelofmetaboliccontrol
that contribute to diabetic nephropathy and raised renal
vascular resistance in these patients. Haemodynamic factors
likeblood pressure controlcouldexplain these variations but
studies have shown conﬂicting results. Ishimura et al. [22]
showed no correlation between RI and PI values and mean
blood pressure however Kim et al. [23]s h o w e das i g n i ﬁ c a n t
co relation of RI and PI values with mean blood pressure.
Our study showed signiﬁcant co relation of RI and PI
values with serum creatinine and eGFR. GFR of subjects
with microalbuminuria was signiﬁcantly lower than subjects
without proteinuria. This emphasizes thepoint that microal-
buminuria is not a very good marker for early detection of
diabeticnephropathy sincefall inGFRhas already set inonce
microalbuminuria develops,and hence the need to identify a
more early marker.
RI and PI values of all diabetics were 0.805 ± 0.187
and 1.63 ± 0.831, which was signiﬁcantly higher than that
of controls. Intragroup comparison showed signiﬁcant dif-
ferences between groups except between groups with and
without microalbuminuria, that is, RI was raised even before
microalbuminuria started. There were 2 patients with serum
creatinine > 1.5, that is, with already set-in renal failure but
still no microalbuminuria. No correlation of RI or PI was
found with amount of proteinuria on univariate analysis.
Kim et al. [23] cited a signiﬁcant correlation of 24-hour
protein value with RI Hamano et al. [24]d i dn o ts h o w
any correlation with amount of proteinuria as a continuous
variable on univariate analysis. However both Hamano et al.
[24] and Ljubiæ et al. [25] showed signiﬁcant correlation
of RI with proteinuria on multivariate stepwise regression
analysis.
Another issue that has been addressed in various studies
is that diabetic nephropathy has been demonstrated to
have higher renal vascular resistance than other causes of
CKD [26]. This led to the postulation that there is some
speciﬁc pathophysiology to diabetes that causes this raised
renal vascular resistance. Although diabetic nephropathy has
been classically described as a microvascular complication,
however there is another school of thought that thinks that
diabetic nephropathy and raised renal resistance are a part
of accelerated diﬀuse atherosclerotic process and widespread
endothelial dysfunction that accompanies diabetes. This is
based on several observations that renal vascular resistance
is particularly higher in patients with lower limb vascular
disorders in diabetes. Also pathological studies have shown
arterial sclerosis in kidney biopsy of medium-sized arteries
perpendiculartothekidneysurface.Thereforeseveralstudies
have tried to correlate RI and PI with markers of macrovas-
cular disease such as Carotid intimo-medial thickness (IMT)
and aortic stiﬀness parameters like brachial ankle pulse wave
velocity (ba-PWV) and ankle brachial pressure index (ABI).6 International Journal of Vascular Medicine
In our study we excluded patients with macrovascular
complicationsandstillfoundsigniﬁcanthigherRIvalues.We
also demonstrated a signiﬁcant correlation of stage of retinal
disease with RI & PI values which itself is a microvascular
complication. There was signiﬁcant diﬀerence between RI &
PI values of stage 4 versus normal, stage 2 versus normal,
and stage 2 versus stage 1. PI also corelated with stage of
fundal disease with higher values in higher retinal stage. This
suggests that raised renal vascular resistance starts due to
diabetic microvascular pathophysiology and at a later date
may get accelerated due to accompanying macro vascular
complication.
Therefore we from above ﬁndings conclude that RI
and PI as an indices of renal vascular resistance are an
early marker for recognition of diabetic nephropathy and
also are predictive factorsof recognition of patients at risk
for future development of diabetic nephropathy. However
this exercise is useful only if we have measures to retard
progression of these patients to diabetic nephropathy. One
of the useful interventions is ACE/ARB, which in numerous
studies have shown beneﬁcial eﬀect on prognosis of diabetic
nephropathy.InourstudydiabeticpatientsonACE/ARBhad
signiﬁcantly lower PI values than patients not on ACE/ARB
and nonsigniﬁcantly lower RI values; in spite of similar age,
blood pressure, and glycemic control.
Another important ﬁnding of ourstudy was that patients
on insulin had signiﬁcantly lower RI and PI values, in spite
of similar age, blood sugar and blood pressure control, and
proteinuria. Several studies indicate that insulin deﬁciency
per se contributes to the neovascularization, increased sur-
face area and aﬀerent arteriolar dilation in diabetes. Several
studies show that physiological concentrations of insulin
cause aﬀerent arteriolar constriction and eﬀerent arteriolar
dilation.These observationsstrongly supportthenotionthat
insulin deﬁciency directly contributes, at least in part, to
the glomerular hypertension in diabetes. Some studies have
addressed diﬀerential class eﬀect of antidiabetic drugs on
renal vascular resistance. Of note is a study by Pistrosch et al.
[27], which concludedthat rosiglitazone an insulin sensitizer
had beneﬁcial eﬀect on renal vascular resistance as well as
endothelial dysfunction.
However our study has certain limitations in the form
of small sample size, a hospital-based sample, and cross-
sectional nature of the study; hence large longitudinal
population-based studies are required before any clinically
meaningful outcomescan bederivedfrom ourobservations.
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